SOFIE manufactures radiopharmaceuticals and operates a contract manufacturing network serving diagnostic and therapeutic applications. The hiring profile is heavily skewed toward junior operations and manufacturing roles, with active recruitment accelerating across 46 open positions—typical for a production-scale operation managing multi-site compliance and equipment validation. Pain points cluster around manufacturing infrastructure (equipment downtime, calibration gaps, method validation) and regulatory harmonization across sites, suggesting SOFIE is scaling production capacity while tightening QMS and supplier controls under 21 CFR Part 211/212.
SOFIE develops and manufactures radiopharmaceuticals—molecular diagnostic and therapeutic agents used in PET imaging and clinical applications. Founded in 2008 and based in Dulles, Virginia, the company operates a distributed radiopharmaceutical production and distribution network alongside contract manufacturing services for healthcare and research customers. The active project portfolio focuses on manufacturing scale-up: new radiopharmaceutical development, equipment commissioning and qualification, analytical method validation, and production protocol implementation across multiple sites. The company manages complex regulatory requirements inherent to radiochemistry and clinical-grade pharmaceutical manufacturing.
SOFIE develops and manufactures radiopharmaceuticals for molecular imaging and therapeutics, with a focus on PET imaging applications. The company operates a distribution network and contract manufacturing services for healthcare organizations and research institutions.
SOFIE's pain points center on 21 CFR Part 211 and 212 compliance, equipment qualification and calibration maintenance, supplier quality harmonization across multiple sites, and method validation for new radiopharmaceuticals.
Other companies in the same industry, closest in size